NCT02605785 A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
| NCT ID | NCT02605785 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Progressive Supranuclear Palsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 332 participants |
| Start Date | 2015-11 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 332 participants in total. It began in 2015-11 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).
Eligibility Criteria
Inclusion Criteria: * Must be over 35 years of age and present with gradual progression of PSP-related symtoms * Must have an informant or study partner that can provide independent information of functioning. * Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset. Exclusion Criteria: * Subjects will be excluded if they meet criteria for another neurodegenerative disease (including corticobasal syndrome, frontotemporal dementia, primary progressive aphasia, Alzheimer's disease, multiple system atrophy and Parkinson's disease) or do not have the symptoms necessary to fulfill inclusion criteria for possible PSP. * Subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded. * Women that are pregnant or post-partum and breast-feeding will be excluded. * Subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome. * Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy). * Subjects will also be excluded if they do not have an informant, or do not consent to research.
Contact & Investigator
Jennifer Whitwell, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT02605785 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, studying Progressive Supranuclear Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02605785 currently recruiting?
Yes, NCT02605785 is actively recruiting participants. Contact the research team at boland.sarah@mayo.edu for enrollment information.
Where is the NCT02605785 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT02605785 clinical trial?
NCT02605785 is sponsored by Mayo Clinic. The principal investigator is Jennifer Whitwell, PhD at Mayo Clinic. The trial plans to enroll 332 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.